Screener Summaries Updates Institutions Sign In More Updates › Other Events › HUMA Other Events · Jun 10, 2026
Humacyte, Inc. announced the presentation of Phase 3 clinical trial (V012) results for its acellular tissue engineered… HUMA Humacyte, Inc.
Humacyte, Inc. announced the presentation of Phase 3 clinical trial (V012) results for its acellular tissue engineered vessel (ATEV) in arteriovenous access for female patients with end-stage renal disease. The company also released an investor presentation. Humacyte, Inc. is a biotechnology company developing tissue engineered medical products.
More from Humacyte, Inc. Humacyte appoints Scott Coward and Paul Kuznik to its Board of Directors Sep 28, 2026 Humacyte reported second quarter 2026 results showing commercial sales of Symvess increased to $0.4 million from $0.1… Aug 12, 2026 Humacyte, Inc. received a notification from Nasdaq on July 31, 2026, that its common stock failed to maintain the… Jul 31, 2026 Humacyte, Inc. entered into an underwriting agreement with Barclays Capital Inc., BTIG, LLC, and Titan Partners Group… Jun 11, 2026 At its 2026 Annual Meeting of Stockholders on June 9, 2026, Humacyte, Inc. stockholders approved an amendment to the… Jun 9, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
